- Page 2 and 3: PRINCIPLES OFPSYCHOPHARMACOLOGYFOR
- Page 4 and 5: Copyright © 2006 by John Wiley & S
- Page 6 and 7: CONTENTSPrefaceFaculty Disclosurexv
- Page 12 and 13: CONTENTSxiii11.2 Cluster A: Odd and
- Page 14 and 15: PREFACEWhy buy a book about psychop
- Page 16 and 17: xviiiFACULTY DISCLOSURESpeakers Bur
- Page 18 and 19: 1INTRODUCTION ANDOVERVIEWWhy a book
- Page 20 and 21: INTRODUCTION AND OVERVIEW 3most imp
- Page 22 and 23: INTRODUCTION AND OVERVIEW 5in this
- Page 24 and 25: ADDITIONAL READING 7ADDITIONAL READ
- Page 26 and 27: 10 BASICS OF PSYCHOPHARMACOLOGYendo
- Page 28 and 29: 12 BASICS OF PSYCHOPHARMACOLOGYa st
- Page 30 and 31: 14 BASICS OF PSYCHOPHARMACOLOGY2.2.
- Page 32 and 33: 16 BASICS OF PSYCHOPHARMACOLOGYthus
- Page 34 and 35: 18 BASICS OF PSYCHOPHARMACOLOGYextr
- Page 36 and 37: 20 BASICS OF PSYCHOPHARMACOLOGYmajo
- Page 38 and 39: 22 BASICS OF PSYCHOPHARMACOLOGYsuch
- Page 40 and 41: 24 BASICS OF PSYCHOPHARMACOLOGYTABL
- Page 42 and 43: 26 BASICS OF PSYCHOPHARMACOLOGYmole
- Page 44 and 45: 28 BASICS OF PSYCHOPHARMACOLOGYFort
- Page 46 and 47: 30 BASICS OF PSYCHOPHARMACOLOGYare
- Page 48 and 49: 32 BASICS OF PSYCHOPHARMACOLOGYMedi
- Page 50 and 51: 34 BASICS OF PSYCHOPHARMACOLOGYClin
- Page 52 and 53: 3MOOD DISORDERS3.1 INTRODUCTIONThe
- Page 54 and 55: MAJOR DEPRESSIVE DISORDER 393.2 MAJ
- Page 56 and 57: MAJOR DEPRESSIVE DISORDER 41The rea
- Page 58 and 59:
MAJOR DEPRESSIVE DISORDER 43als add
- Page 60 and 61:
MAJOR DEPRESSIVE DISORDER 45TABLE 3
- Page 62 and 63:
MAJOR DEPRESSIVE DISORDER 47TABLE 3
- Page 64 and 65:
MAJOR DEPRESSIVE DISORDER 49provide
- Page 66 and 67:
MAJOR DEPRESSIVE DISORDER 51avoid t
- Page 68 and 69:
MAJOR DEPRESSIVE DISORDER 53TABLE 3
- Page 70 and 71:
MAJOR DEPRESSIVE DISORDER 55Infrequ
- Page 72 and 73:
MAJOR DEPRESSIVE DISORDER 57attenti
- Page 74 and 75:
MAJOR DEPRESSIVE DISORDER 59is one
- Page 76 and 77:
TABLE 3.10. Cytochrome P 450 Intera
- Page 78 and 79:
MAJOR DEPRESSIVE DISORDER 63in the
- Page 80 and 81:
Epilepsy SSRIs ECT MAOIs BupropionD
- Page 82 and 83:
MAJOR DEPRESSIVE DISORDER 67depress
- Page 84 and 85:
DYSTHYMIC DISORDER 69TABLE 3.12. Di
- Page 86 and 87:
BIPOLAR DISORDERS 713.4 BIPOLAR DIS
- Page 88 and 89:
BIPOLAR DISORDERS 73short of that a
- Page 90 and 91:
BIPOLAR DISORDERS 75opposed to inso
- Page 92 and 93:
BIPOLAR DISORDERS 77addition, the h
- Page 94 and 95:
BIPOLAR DISORDERS 79TABLE 3.16. Com
- Page 96 and 97:
BIPOLAR DISORDERS 81especially high
- Page 98 and 99:
BIPOLAR DISORDERS 83vomiting, dyspe
- Page 100 and 101:
BIPOLAR DISORDERS 85excreted unchan
- Page 102 and 103:
BIPOLAR DISORDERS 87Aripiprazole (A
- Page 104 and 105:
BIPOLAR DISORDERS 89tion from bipol
- Page 106 and 107:
BIPOLAR DISORDERS 91doses of a benz
- Page 108 and 109:
ADDITIONAL READING 93Sleep is anoth
- Page 110 and 111:
ADDITIONAL READING 95book of Psycho
- Page 112 and 113:
98 SCHIZOPHRENIATABLE 4.1. Diagnost
- Page 114 and 115:
100 SCHIZOPHRENIAsimply does not fu
- Page 116 and 117:
102 SCHIZOPHRENIAIn DSM-IV parlance
- Page 118 and 119:
104 SCHIZOPHRENIAlegal baggage, sch
- Page 120 and 121:
106 SCHIZOPHRENIAprovided by friend
- Page 122 and 123:
108 SCHIZOPHRENIAwas never widely u
- Page 124 and 125:
110 SCHIZOPHRENIA(Haldol) or fluphe
- Page 126 and 127:
112 SCHIZOPHRENIATABLE 4.6. Antipsy
- Page 128 and 129:
114 SCHIZOPHRENIAMolindone (Moban).
- Page 130 and 131:
116 SCHIZOPHRENIA• Less prone to
- Page 132 and 133:
118 SCHIZOPHRENIAMore common than s
- Page 134 and 135:
120 SCHIZOPHRENIAAripiprazole (Abil
- Page 136 and 137:
122 SCHIZOPHRENIAAn adequate trial
- Page 138 and 139:
124 SCHIZOPHRENIAFor patients in wh
- Page 140 and 141:
5ANXIETY DISORDERS5.1 INTRODUCTION5
- Page 142 and 143:
INTRODUCTION 1295.1.3 Brief Overvie
- Page 144 and 145:
INTRODUCTION 131patient abruptly st
- Page 146 and 147:
TABLE 5.3. BenzodiazepinesGeneric T
- Page 148 and 149:
INTRODUCTION 135duloxetine (Cymbalt
- Page 150 and 151:
PANIC DISORDER 137TABLE 5.4. Panic
- Page 152 and 153:
PANIC DISORDER 139The referral for
- Page 154 and 155:
PANIC DISORDER 141thyroid profile,
- Page 156 and 157:
PANIC DISORDER 143However, there ar
- Page 158 and 159:
GENERALIZED ANXIETY DISORDER 145Unf
- Page 160 and 161:
GENERALIZED ANXIETY DISORDER 147add
- Page 162 and 163:
GENERALIZED ANXIETY DISORDER 149syn
- Page 164 and 165:
GENERALIZED ANXIETY DISORDER 151Ant
- Page 166 and 167:
OBSESSIVE-COMPULSIVE DISORDER 153TA
- Page 168 and 169:
OBSESSIVE-COMPULSIVE DISORDER 155an
- Page 170 and 171:
OBSESSIVE-COMPULSIVE DISORDER 157se
- Page 172 and 173:
SOCIAL ANXIETY DISORDER (SOCIAL PHO
- Page 174 and 175:
SOCIAL ANXIETY DISORDER (SOCIAL PHO
- Page 176 and 177:
SOCIAL ANXIETY DISORDER (SOCIAL PHO
- Page 178 and 179:
SOCIAL ANXIETY DISORDER (SOCIAL PHO
- Page 180 and 181:
POST-TRAUMATIC STRESS DISORDER 167m
- Page 182 and 183:
POST-TRAUMATIC STRESS DISORDER 169I
- Page 184 and 185:
POST-TRAUMATIC STRESS DISORDER 171O
- Page 186 and 187:
POST-TRAUMATIC STRESS DISORDER 173I
- Page 188 and 189:
ADDITIONAL READING 175commonly empl
- Page 190 and 191:
6SUBSTANCE USE DISORDERS6.1 INTRODU
- Page 192 and 193:
INTRODUCTION 179withdrawal contribu
- Page 194 and 195:
BRIEF DESCRIPTION AND DIAGNOSTIC CR
- Page 196 and 197:
PREVALENCE AND RISK FACTORS 1836.3
- Page 198 and 199:
PRESENTATION AND CLINICAL COURSE 18
- Page 200 and 201:
INITIAL EVALUATION AND DIFFERENTIAL
- Page 202 and 203:
HISTORY OF TREATMENT 189acts pharma
- Page 204 and 205:
CURRENT APPROACHES TO TREATMENT 191
- Page 206 and 207:
ALCOHOL USE DISORDERS 193detoxifica
- Page 208 and 209:
ALCOHOL USE DISORDERS 195of major d
- Page 210 and 211:
ALCOHOL USE DISORDERS 197multivitam
- Page 212 and 213:
COCAINE USE DISORDERS 199Dopamine-S
- Page 214 and 215:
OPIATE USE DISORDERS 201vulnerable
- Page 216 and 217:
OPIATE USE DISORDERS 203therapies s
- Page 218 and 219:
OPIATE USE DISORDERS 205azolam (Ver
- Page 220 and 221:
7EATING DISORDERS7.1 INTRODUCTIONDi
- Page 222 and 223:
ANOREXIA NERVOSA 209TABLE 7.1. Clin
- Page 224 and 225:
ANOREXIA NERVOSA 211Numerous risk f
- Page 226 and 227:
ANOREXIA NERVOSA 213therefore must
- Page 228 and 229:
ANOREXIA NERVOSA 215preferable to t
- Page 230 and 231:
BULIMIA NERVOSA 217TABLE 7.5. Manag
- Page 232 and 233:
BULIMIA NERVOSA 219Onset of the dis
- Page 234 and 235:
BULIMIA NERVOSA 2217.3.5 History of
- Page 236 and 237:
BULIMIA NERVOSA 223struggles with c
- Page 238 and 239:
BINGE-EATING DISORDER 2257.4.2 Prev
- Page 240 and 241:
BINGE-EATING DISORDER 227In summary
- Page 242 and 243:
ADDITIONAL READING 229During acute
- Page 244 and 245:
8ATTENTION DEFICIT-HYPERACTIVITY DI
- Page 246 and 247:
PREVALENCE AND RISK FACTORS 233to d
- Page 248 and 249:
PRESENTATION AND CLINICAL COURSE 23
- Page 250 and 251:
INITIAL EVALUATION AND DIFFERENTIAL
- Page 252 and 253:
HISTORY OF PHARMACOLOGICAL TREATMEN
- Page 254 and 255:
HISTORY OF PHARMACOLOGICAL TREATMEN
- Page 256 and 257:
HISTORY OF PHARMACOLOGICAL TREATMEN
- Page 258 and 259:
HISTORY OF PHARMACOLOGICAL TREATMEN
- Page 260 and 261:
HISTORY OF PHARMACOLOGICAL TREATMEN
- Page 262 and 263:
CURRENT APPROACH TO TREATMENT 249of
- Page 264 and 265:
TABLE 8.3. Medications Commonly Use
- Page 266 and 267:
CURRENT APPROACH TO TREATMENT 253ch
- Page 268 and 269:
ADDITIONAL READING 255Despite these
- Page 270 and 271:
258 SLEEP DISORDERSare having probl
- Page 272 and 273:
260 SLEEP DISORDERScommon complaint
- Page 274 and 275:
262 SLEEP DISORDERSnia, suffering f
- Page 276 and 277:
264 SLEEP DISORDERSNighttime Moveme
- Page 278 and 279:
266 SLEEP DISORDERSOther important
- Page 280 and 281:
268 SLEEP DISORDERSBarbiturates. Th
- Page 282 and 283:
270 SLEEP DISORDERSinsomnia. Second
- Page 284 and 285:
272 SLEEP DISORDERSGabapentin (Neur
- Page 286 and 287:
274 SLEEP DISORDERShow much they in
- Page 288 and 289:
276 SLEEP DISORDERSTABLE 9.5. Diagn
- Page 290 and 291:
278 SLEEP DISORDERSbeen stimulants
- Page 292 and 293:
280 SLEEP DISORDERSintrusions of RE
- Page 294 and 295:
282 SLEEP DISORDERSMitler MM, Haydu
- Page 296 and 297:
284 ALZHEIMER’S DISEASE AND OTHER
- Page 298 and 299:
286 ALZHEIMER’S DISEASE AND OTHER
- Page 300 and 301:
288 ALZHEIMER’S DISEASE AND OTHER
- Page 302 and 303:
290 ALZHEIMER’S DISEASE AND OTHER
- Page 304 and 305:
292 ALZHEIMER’S DISEASE AND OTHER
- Page 306 and 307:
294 ALZHEIMER’S DISEASE AND OTHER
- Page 308 and 309:
296 ALZHEIMER’S DISEASE AND OTHER
- Page 310 and 311:
298 ALZHEIMER’S DISEASE AND OTHER
- Page 312 and 313:
300 ALZHEIMER’S DISEASE AND OTHER
- Page 314 and 315:
302 ALZHEIMER’S DISEASE AND OTHER
- Page 316 and 317:
304 ALZHEIMER’S DISEASE AND OTHER
- Page 318 and 319:
306 ALZHEIMER’S DISEASE AND OTHER
- Page 320 and 321:
308 ALZHEIMER’S DISEASE AND OTHER
- Page 322 and 323:
310 ALZHEIMER’S DISEASE AND OTHER
- Page 324 and 325:
11PERSONALITY DISORDERS11.1 INTRODU
- Page 326 and 327:
INTRODUCTION 31511.1.2 Defining a P
- Page 328 and 329:
CLUSTER A: ODD AND ECCENTRIC PERSON
- Page 330 and 331:
CLUSTER A: ODD AND ECCENTRIC PERSON
- Page 332 and 333:
CLUSTER A: ODD AND ECCENTRIC PERSON
- Page 334 and 335:
CLUSTER B: DRAMATIC AND EMOTIONAL P
- Page 336 and 337:
CLUSTER B: DRAMATIC AND EMOTIONAL P
- Page 338 and 339:
CLUSTER B: DRAMATIC AND EMOTIONAL P
- Page 340 and 341:
CLUSTER B: DRAMATIC AND EMOTIONAL P
- Page 342 and 343:
CLUSTER C: ANXIOUS AND FEARFUL PERS
- Page 344 and 345:
CLUSTER C: ANXIOUS AND FEARFUL PERS
- Page 346 and 347:
ADDITIONAL READING 33511.4.5 Curren
- Page 348 and 349:
12TRAUMATIC BRAIN INJURY12.1 INTROD
- Page 350 and 351:
INTRODUCTION 339medical disease or
- Page 352 and 353:
APPROACHES TO TREATMENT 341sion tom
- Page 354 and 355:
TABLE 12.1. Medication Strategies f
- Page 356 and 357:
APPROACHES TO TREATMENT 345for slee
- Page 358 and 359:
APPROACHES TO TREATMENT 347symptoms
- Page 360 and 361:
APPROACHES TO TREATMENT 349that typ
- Page 362 and 363:
APPROACHES TO TREATMENT 351we prefe
- Page 364 and 365:
13MANAGING SIDE EFFECTS13.1 INTRODU
- Page 366 and 367:
INTRODUCTION 355As we move forward
- Page 368 and 369:
INTRODUCTION 357seen much more freq
- Page 370 and 371:
INTRODUCTION 359ends or stop taking
- Page 372 and 373:
NOREPINEPHRINE-RELATED SIDE EFFECTS
- Page 374 and 375:
DOPAMINE-RELATED SIDE EFFECTS 363po
- Page 376 and 377:
DOPAMINE-RELATED SIDE EFFECTS 365st
- Page 378 and 379:
DOPAMINE-RELATED SIDE EFFECTS 367ti
- Page 380 and 381:
DOPAMINE-RELATED SIDE EFFECTS 369ta
- Page 382 and 383:
SEROTONIN-RELATED SIDE EFFECTS 371t
- Page 384 and 385:
SEROTONIN-RELATED SIDE EFFECTS 373T
- Page 386 and 387:
SEROTONIN-RELATED SIDE EFFECTS 375i
- Page 388 and 389:
ACETYLCHOLINE-RELATED SIDE EFFECTS
- Page 390 and 391:
HISTAMINE-RELATED SIDE EFFECTS 379T
- Page 392 and 393:
HISTAMINE-RELATED SIDE EFFECTS 381T
- Page 394 and 395:
384 INDEXBenzedrine, see Amphetamin
- Page 396 and 397:
386 INDEXLaryngospasm, 369L-DOPA, 2
- Page 398 and 399:
388 INDEXSabril, see VigabatrinSchi